Literature DB >> 9454581

Systematic study of the six cysteines of the E1 subunit of the pyruvate dehydrogenase multienzyme complex from Escherichia coli: none is essential for activity.

N Nemeria1, A Volkov, A Brown, J Yi, L Zipper, J R Guest, F Jordan.   

Abstract

Variants of the Escherichia coli 1-lip pyruvate dehydrogenase multienzyme complex (1-lip PDHc) with the C259N and C259S substitutions in the putative thiamin diphosphate-(ThDP-) binding motif of the pyruvate dehydrogenase component (E1, EC 1.2.4.1) were characterized. Single substitutions were made at the five remaining cysteines of the E1 component, creating the C120A, C575A, C610A, C654A, and C770S variants to test the hypothesis that the activity loss that accompanies exposure of the enzyme to fluoropyruvate, bromopyruvate, and 2-oxo-3-butynoic acid is the result of the modification of approximately one cysteine residue per E1 monomer. Surprisingly, all single cysteine E1 variants could be reconstituted with E2-E3 subcomplex and showed PDHc activity ranging from 74% to 96% that of the parental enzyme. The specific activities of C259N and C259S variants of 1-lip PDHc were 58% and 27% relative to that of the parental 1-lip PDHc. All five single cysteine E1 variants, along with the C259N and C259S variants of 1-lip PDHc, could also (1) be inactivated with fluoropyruvate and 2-oxo-3-butynoic acid, (2) were subject to inactivation by the monoclonal antibody 18A9 reported from one of our laboratories, and (3) were subject to regulation by pyruvate and acetyl-CoA. It was therefore concluded that none of the six cysteine residues is essential for the activity of the E1 component or of the complex. When tested with the putative transition-state analogue, thiamin 2-thiothiazolone diphosphate, all but the C259S and C259N variants were very potently inhibited, the stoichiometry for parental E1 being about 1.6 mol of inhibitor/mol of E1 subunit. The C259S and C259N E1 variants required at least 25-fold greater inhibitor concentration to achieve the same level of inhibition. C259 is located in the putative thiamin diphosphate-binding motif of the enzyme [more exactly, it is adjacent to a ligand to the Mg(II) ion]. It is therefore concluded that thiamin 2-thiothiazolone diphosphate is not a transition-state analogue; rather, it is a potent inhibitor of the complex because of a specific interaction with the C259 residue.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9454581     DOI: 10.1021/bi9722251

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  13 in total

1.  The 1',4'-iminopyrimidine tautomer of thiamin diphosphate is poised for catalysis in asymmetric active centers on enzymes.

Authors:  Natalia Nemeria; Sumit Chakraborty; Ahmet Baykal; Lioubov G Korotchkina; Mulchand S Patel; Frank Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-20       Impact factor: 11.205

2.  3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects.

Authors:  S M El Sayed; R M Abou El-Magd; Y Shishido; S P Chung; T H Diem; T Sakai; H Watanabe; S Kagami; K Fukui
Journal:  J Bioenerg Biomembr       Date:  2012-02-09       Impact factor: 2.945

3.  Efficient coupling of catalysis and dynamics in the E1 component of Escherichia coli pyruvate dehydrogenase multienzyme complex.

Authors:  Sachin Kale; Gözde Ulas; Jaeyoung Song; Gary W Brudvig; William Furey; Frank Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-23       Impact factor: 11.205

4.  Conformational ensemble modulates cooperativity in the rate-determining catalytic step in the E1 component of the Escherichia coli pyruvate dehydrogenase multienzyme complex.

Authors:  Sachin Kale; Frank Jordan
Journal:  J Biol Chem       Date:  2009-09-29       Impact factor: 5.157

5.  Insight to the interaction of the dihydrolipoamide acetyltransferase (E2) core with the peripheral components in the Escherichia coli pyruvate dehydrogenase complex via multifaceted structural approaches.

Authors:  Krishnamoorthy Chandrasekhar; Junjie Wang; Palaniappa Arjunan; Martin Sax; Yun-Hee Park; Natalia S Nemeria; Sowmini Kumaran; Jaeyoung Song; Frank Jordan; William Furey
Journal:  J Biol Chem       Date:  2013-04-11       Impact factor: 5.157

6.  Structure and function of the catalytic domain of the dihydrolipoyl acetyltransferase component in Escherichia coli pyruvate dehydrogenase complex.

Authors:  Junjie Wang; Natalia S Nemeria; Krishnamoorthy Chandrasekhar; Sowmini Kumaran; Palaniappa Arjunan; Shelley Reynolds; Guillermo Calero; Roman Brukh; Lazaros Kakalis; William Furey; Frank Jordan
Journal:  J Biol Chem       Date:  2014-04-17       Impact factor: 5.157

7.  Acetylphosphinate is the most potent mechanism-based substrate-like inhibitor of both the human and Escherichia coli pyruvate dehydrogenase components of the pyruvate dehydrogenase complex.

Authors:  Natalia S Nemeria; Lioubov G Korotchkina; Sumit Chakraborty; Mulchand S Patel; Frank Jordan
Journal:  Bioorg Chem       Date:  2006-10-27       Impact factor: 5.275

8.  Formation of reactive oxygen species by human and bacterial pyruvate and 2-oxoglutarate dehydrogenase multienzyme complexes reconstituted from recombinant components.

Authors:  Attila Ambrus; Natalia S Nemeria; Beata Torocsik; Laszlo Tretter; Mattias Nilsson; Frank Jordan; Vera Adam-Vizi
Journal:  Free Radic Biol Med       Date:  2015-10-09       Impact factor: 7.376

9.  Competence of Thiamin Diphosphate-Dependent Enzymes with 2'-Methoxythiamin Diphosphate Derived from Bacimethrin, a Naturally Occurring Thiamin Anti-vitamin.

Authors:  Natalia S Nemeria; Brateen Shome; Alicia A DeColli; Kathryn Heflin; Tadhg P Begley; Caren Freel Meyers; Frank Jordan
Journal:  Biochemistry       Date:  2016-02-08       Impact factor: 3.162

10.  Determination of pre-steady-state rate constants on the Escherichia coli pyruvate dehydrogenase complex reveals that loop movement controls the rate-limiting step.

Authors:  Anand Balakrishnan; Natalia S Nemeria; Sumit Chakraborty; Lazaros Kakalis; Frank Jordan
Journal:  J Am Chem Soc       Date:  2012-11-02       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.